IIQ Licences worldwide OC Biomarker IP from UniQuest
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This licence supports the development of Inoviq's EXO-OC test for early detection of ovarian cancer in asymptomatic women. The company is in discussions with clinical laboratories to accelerate the launch of the test in the US. The licensed intellectual property includes patent applications for novel biomarker combinations and methods for the ovarian cancer test. Inoviq plans to commercialise the EXO-OC test as a Laboratory Developed Test in the US before expanding globally.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Inoviq
- CAR-NK EVs kill Breast Cancer Cells in vitro at Peter Mac
- Appendix 4E and Preliminary Financial Report
- Quarterly Business Update and Appendix 4C - June 2025
- INOVIQ Investor Webinar Presentation Slides
- Response to ASX Query
Later from Inoviq
- Trading Halt
- INOVIQ completes $9.5m placement
- Investor Presentation
- IIQ completes placement and lodges SPP Offer Booklet
- Quarterly Business Update and Appendix 4C - September 2025
Follow Inoviq into a list and get an email when it puts out news.
Follow Inoviq